the potential increase in efficacy by conjugation to radioisotopes and other cellular toxins and the ability to characterize the target with clinical laboratory diagnostics to improve the drug's clinical performance, it is anticipated that current and future antibody therapeutics will find substantial roles...
(2003) Antisense oligonucleotide-based therapeutics for cancer. Oncogene, 22, 9087-9096.Dean NM, Bennett CF (2003) Antisense oligonucleotide- based therapeutics for cancer. Oncogene 22:9087-9096.Dean NM, Bennett CF. Antisense oligonucleotide-based thera- peutics for cancer. Oncogene 2003; 22: ...
We are a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. Click on the link below for our latest corporate presentation. LEARN MORE Clinical Trials Information Resources and guides for patients and caregivers. ...
Invivyd is on a mission to rapidly and continually deliver antibody-based therapies that keep pace with the evolving viral threats
We are a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. Click on the link below for our latest corporate presentation. LEARN MOREClinical Trials Information Resources and guides for patients and caregivers. Cl...
Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by exquisite specificity, long serum half-life, high affinity and immune effector functions. In this review, we outline key advances in the field with a particular focus on recent and emerging classes of engineere...
LIFE-CHANGING MEDICINES LEARN MORE Previous Next Overview We are a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. Click on the link below for our latest corporate presentation. ...
A number of strategies have been proposed to limit the immunogenicity of antibody-based therapeutics and manage patients prior and during treatment with these agents. Beyond the use of fully human/humanized mAbs, which is already widely implemented owing to technological advances in antibody development...
Klakamp, Scott L.Springer New YorkTabrizi, MA, Bornstein, GG, Klakamp, SL (2012) Development of antibody-based therapeutics: translational considerations. Springer, New YorkM.A. Tabrizi, G.G. Bornstein, S.L. Klakamp, Development of antibody-based therapeutics :...
Despite the fact that the new drugs and targeted therapies have been approved for cancer therapy during the past 30 years, the majority of cancer types are still remain challenging to be treated. Due to the tumor heterogeneity, immune system evasion and the complex interaction between the tumor ...